IMMUNE CHECKPOINT INHIBITORS
Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy are at an Increased Risk for Atherosclerotic Cardiovascular Disease
In this paper, the authors hypothesize that patients with cancer receiving immune checkpoint inhibitor therapy are at an increased risk of late-effect atherosclerosis-related cardiovascular disease, and review findings from the sparse data that is currently available on this topic.
Journal for ImmunoTherapy of CancerMeet the Faculty
Videos
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
